Board summary
Key figures
31,797
Registered population
56.8% aged 18–64
25.4%
Aged 65+
ICB 19.0% · England 17.9%
4.2%
Ethnic minority (non-White)
1.8% Asian · England 9.6%
20.8%
In IMD quintile 1
ICB 31.9% · England 21.0%
~6,509
Core20 residents (est.)
Resident basis; registered basis ~7,045 · see page 3
6,167
Hypertension register
+6.18% in 3 yrs · England +5.60%
323
SMI register
8.1% of Wirral (LAD)'s
908
COPD register
Reviews +23.74% in 3 yrs
Forecast to 2030
7,137
Hypertension patients, 2030
+970 on today
69.6%
QRISK ≥20% on statins, 2030
+3.40pp over 3 yrs
6.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual review coverage trails comparators.
Annual asthma review coverage is 54.9% against 63.2% in Wirral and 65.7% in England, leaving 1,025 registered patients without a recorded review.
Age-five MMR2 coverage drops below target.
In the age-five cohort of 79 children, MMR2 coverage is 87.3%, which is 7.6 pp below MMR1 (94.9%) and 7.7 pp below the 95.0%.
Breast screening coverage exceeds national benchmark.
Breast screening coverage for ages 53 to 70 reaches 74.2% (Wirral 72.6%, England 69.9%), following +13.2% three-year growth (England +8.4%).
Population, age and ethnicity
Patients aged 65+ make up 25.4% of the list, well above England's 17.9%
Across four practices, MORETON AND MEOLS PCN serves 31,797 registered patients, with an older demographic profile. Patients aged 65+ account for 25.4% (8,074 patients), notably above Wirral (20.7%), the ICB (19.0%) and England (17.9%). Working-age adults (18–64) comprise 56.8% (18,069) and children (0–17) 17.8% (5,654). Based on Census usual residents rather than registered patients, 95.8% identify as White, above Wirral (95.2%), the ICB (93.0%) and England (81.1%), with an ethnic minority share of 4.2%. This older age structure could heighten demand for complex chronic condition management and frailty services.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Wirral (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Wirral LA) | 1,517 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.1% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 54.2% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Wirral LA) | 753 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Wirral LA) | 25.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
PCN Core20 share is 20.8%, but practice deprivation spans 36.1 percentage points
The PCN Core20 cohort is 20.8%, near England (21.0%) but below Wirral (34.8%) and the ICB (31.9%), with average IMD decile 5.7. Practice deprivation spans 36.1 percentage points: Moreton Group Practice has 36.1% Core20 share (4,823 estimated patients) and Moreton Medical Centre has 26.0% (1,332 estimated patients), while Hoylake & Meols Medical Ctr records 0.0%. Weighted practice share is 22.2%, with a 1.39 percentage points reconciliation difference. Observation periods were not supplied. Deprivation is unevenly distributed across member practices, suggesting outreach could focus resources where need is clustered.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
323
SMI register
1.02% recorded prevalence
214
Learning disability register
0.68% recorded prevalence
18
Care homes, 635 beds
In the PCN catchment
10.9%
Provide unpaid care
Wirral (LAD), Census 2021
The PCN records 323 patients on its severe mental illness register (1.0%, matching England) and 214 on its learning disability register (0.7%, above England's 0.6% but below Wirral's 0.8%). Its catchment includes 18 care homes with 635 beds, though resident registrations are unverified.
Severe mental illness: physical health checks
Severe mental illness prevalence is 1.0% (England 1.0%). Recorded blood pressure checks reach 88.4% (England 83.4%), and BMI checks reach 82.6% (England 82.1%). However, full health check packages are unmeasured, so individual element completion cannot confirm comprehensive physical checks.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,167
Hypertension register
+6.18%
Register growth, 3 yrs
Wirral (LAD) +6.35% · England +5.60%
+3.46pp
BP control, under 80
≤140/90 · +3.63pp aged 80+
+970
More patients by 2030
Forecast 7,137 (21.96%)
Hypertension case-finding and control
Hypertension recorded prevalence is 19.5% (6,167 patients), above Wirral (18.0%), the ICB (16.8%) and England (15.2%). While 89.8% of patients have a recent blood pressure reading (England 90.0%), blood pressure control under 80 years is 63.8%, below Wirral (66.5%), the ICB (66.4%) and England (67.8%). Across all hypertension patients, 66.7% are treated to target (England 70.3%). In heart failure, annual reviews fell 5.5% over three years (England +8.7%) to 66.6% (England 78.5%). Denominators include personalised care adjustments and crude prevalence is not age-adjusted. Trailing national control rates indicates that clinical titration and heart failure recall capacity warrant prioritisation across the cardiovascular cohort.
Lipids and statins
For primary prevention, 62.2% of patients with QRISK ≥ 20% receive lipid-lowering therapy, below Wirral (65.8%) and England (63.6%). In secondary prevention, diabetes patients with cardiovascular disease on a statin fell 2.0% over three years (England +1.0%) to 82.7% (England 84.4%). Lower coverage than England indicates an opportunity to review lipid therapy recall.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 66,137 | £2.20 | £1.71 | £1.86 | £145,501 |
| Cardiovascular (all), 2025 | 91,287 | £5.37 | £4.37 | £3.33 | £490,211 |
In 2026, lipid-modifying drugs cost £2.20 per item across 66,137 items (spend £145,501), above England (£1.86), Wirral (£2.00) and the ICB (£1.71), representing £22,487 more than at England's unit cost. This cost indicator does not reflect clinical appropriateness. Higher unit spend than comparators indicates an opportunity to review prescribing choices against formulary guidance.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+15.66%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.38%
Asthma prevalence, PCN 3-yr % change
Recorded prevalence exceeds England for COPD (2.9% vs 1.9%) and asthma (7.5% vs 6.6%), covering 908 and 2,271 patients. Despite 3-year review changes of +23.7% in COPD (England +2.8%) and +15.7% in asthma (England +4.4%), annual review rates lag England at 70.3% (England 76.4%) and 54.9% (England 65.7%), leaving an estimated 1,025 asthma patients unreviewed. Prescribing for ages 5-19 reaches 2,405 items per 1,000 (England 1,488). Lagging reviews may reflect recall pressures, locally unverified; a recall audit would test it.
Cancer register and children's immunisation
Cancer prevalence is 5.4% (1,699 patients), above England's 3.8%. In childhood immunisations, 6-in-1 complete course reaches 98.1% at 24 months. However, in the age-5 cohort, MMR dose 2 drops to 87.3%, trailing dose 1 (94.9%) by 7.6 pp and falling 7.7 pp below the 95.0% target alongside the 4-in-1 booster (87.3%). This pre-school drop-off could reflect recall timing, locally unverified; a practice recall audit would test it.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In 2022, 55.5% of cancers with a known stage across NHS Cheshire and Merseyside ICB were diagnosed at stage 1 or 2 (7,482 of 13,490), in line with England (55.3%) but 19.5 pp below the 75.0% national ambition by 2028 (about 2,640 additional cases needed). Known stage was recorded for 72.8% of 18,522 registered cancers (England 67.0%). Across the PCN, cervical screening among women aged 25 to 49 is 71.7% (England 66.8%, Wirral 71.5%) with a three-year change of -1.4% (England -1.0%), while Moreton Group Practice records 69.6%. These wider-system staging figures do not measure PCN performance, but practice-level recall audits could support earlier diagnosis.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026, Wirral University Teaching Hospital NHS Foundation Trust met the 62-day cancer standard for 77.6% of pathways (standard 85.0%), above England (71.2%) and the ICB (76.2%), compared with Liverpool University Hospitals NHS Foundation Trust (73.3%) and Mersey and West Lancashire Teaching Hospitals NHS Trust (78.0%). Faster diagnosis at 28 days reached 74.7% (standard 75.0%, ICB 77.2%, England 79.3%). In diagnostics, colonoscopy 6+ week waits were 32.8% (England 30.8%), whereas MRI (1.5%) and CT (1.5%) sat below England (21.4% and 9.9%). These provider figures describe wider-system access and indicate lower GI diagnostic waits to raise with system partners.
| Pathways within standard (%) | Wirral | Liverpool | Mersey and West Lancashire | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.71 | 75.47 | 72.39 | 77.25 | 79.32 |
| 31-day treatment (96%) | 92.53 | 90.51 | 95.46 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 77.65 | 73.26 | 77.96 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Wirral | Liverpool | Mersey and West Lancashire | England |
|---|---|---|---|---|
| MRI | 1.54 | 6.42 | 14.04 | 21.40 |
| CT | 1.55 | 0.71 | 13.08 | 9.92 |
| Echocardiography | 5.07 | 12.55 | 34.88 | 28.48 |
| Colonoscopy | 32.81 | 33.14 | 18.04 | 30.83 |
| Gastroscopy | 17.73 | 44.99 | 18.17 | 29.02 |
| All 15 DM01 tests | 5.02 | 11.50 | 21.17 | 23.14 |
| Community services activity | Wirral residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 58,870 | 541,280 |
| Referrals | 13,315 | 97,150 |
| Patients with a contact | 17,205 | 146,240 |
Community services (residents of Wirral), Jun 2026 (provisional). In Jun 2026, 66.1% of community service contacts for Wirral residents were with adults aged 65 and over (38,930 of 58,870 contacts). While borough-level rather than PCN-specific, this volume highlights strong reliance on community teams to manage older patients with complex needs.
Practice variation and patient experience
Overall patient satisfaction exceeds England, while practice vaccination achievement spans 25.5 pp
In 2025/26, overall QOF achievement spanned from 86.3% at Hoylake Rd Met Ctr to 95.0% at Moreton Group Practice (England 92.5%). Vaccination achievement varied by 25.5 pp, from 30.2% at Hoylake Rd Met Ctr to 55.7% at Moreton Group Practice (England 55.2%). This could reflect call-recall differences, though unverified locally; practice audits would test it.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Hoylake Rd Met Ctr | 112 | 17.6 | 71.3% | 72.2% | 91.7% |
| Moreton | 118 | 26.0 | 72.8% | 73.4% | 89.0% |
| Moreton | 108 | 36.1 | 64.9% | 85.4% | 86.9% |
| Hoylake & Meols | 116 | 0.0 | 68.3% | 77.6% | 79.6% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Nine measures trail national three-year progress while dementia register growth reached +16.0%
Nine clinical measures trail England over three years. Heart failure annual reviews fell 5.5% (England +8.7%), trailing by 14.23 points to leave current coverage at 66.6% against England's 78.5%. Statin coverage for diabetes patients with cardiovascular disease fell 2.0% (England +1.0%), trailing by 2.99 points. Review delivery increased in other areas: COPD reviews rose +23.7% (England +2.8%) and asthma reviews grew +15.7% (England +4.4%), while breast screening rose +13.2% (England +8.4%). Prioritising cardiovascular recalls could help reverse multi-year review declines.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Diabetes statin (CVD)
Hypertension BP reading
COPD register
QRISK statin treatment
COPD reviews
Asthma reviews
Breast screening (53-70)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Wirral (LAD) | Asset | PCN | Wirral (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 18 (635 beds) | n/a | Schools (catchment) | 45 | n/a |
| Children's centres | 2 | 16 | Places of worship | 32 | 171 |
| Libraries | 4 | 18 | Primary schools (LA maintained) | 10 | 52 |
| Primary academies | 6 | 36 | Special schools | 1 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma annual review coverage is 54.9% on a register of 2,271 patients (7.5% prevalence), below England (65.7%) by 10.8 pp and Wirral (63.2%) by 8.3 pp, leaving 1,025 unreviewed. For discussion: run a structured asthma review recall using a single template and flexible slots at high-Core20 practices. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Pre-school booster and MMR2 recall
In the age-5 cohort (79 children), MMR2 (87.3%) trails MMR1 (94.9%) by 7.6 pp, and MMR2 and the 4-in-1 booster (87.3%) sit 7.7 pp below the 95.0% target. For discussion: cross-check age-5 lists for children with MMR1 but no MMR2 or 4-in-1 booster, offering catch-up slots. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Hypertension and heart failure review
Across 6,167 hypertension patients (19.5% prevalence), under-80 BP control is 63.8% (England 67.8%) and overall control is 66.7% (England 70.3%). Across 551 heart failure patients, reviews fell 5.5% to 66.6% (England 78.5%). For discussion: run pharmacist-led titration recall for uncontrolled under-80 hypertension and structured recall for heart failure reviews. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Anticipatory frailty and care planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 practice outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Hypertension blood pressure recall (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Digital access and website audit (p9) | GPPS easy to contact the practice using its website | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Pre-school booster and MMR2 recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · Hypertension and heart failure review (p12) | Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
